Summary
Updated Aug 31, 2026
Shlomo Yanai is Director of Amneal Pharmaceuticals, Inc. (AMRX). 2 SEC Form 4 filings on record, most recently on 8 May 2026.
Recent Transactions
2Every recent SEC Form 4 transaction Shlomo Yanai has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Shlomo Yanai go back to 2026: 2 primary Form 4 filings, an average of 2.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Shlomo Yanai files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jacek Olczak - $14.57M of PM open-market activity in the last 12 months
- Emmanuel Babeau - $6.14M of PM open-market activity in the last 12 months
- Nikita Shah - $4.14M of AMRX open-market activity in the last 12 months
- Jason B. Daly - $3.77M of AMRX open-market activity in the last 12 months
- Wilde Frederic de - $3.65M of PM open-market activity in the last 12 months
- Stacey Kennedy - $2.63M of PM open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Shlomo Yanai?
Shlomo Yanai is a corporate insider, tracked as Director of Amneal Pharmaceuticals, Inc. (AMRX). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Shlomo Yanai last file a Form 4?
The most recent primary Form 4 on record is dated 8 May 2026, one of 2 filings going back to 2026.
Where can I see all of Shlomo Yanai's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Shlomo Yanai and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial